Dr. Miriam and Sheldon G. Adelson Clinic for Drug Abuse Treatment and Research, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel,
Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel,
Eur Addict Res. 2021;27(3):198-205. doi: 10.1159/000511898. Epub 2020 Nov 26.
As CRH-binding protein (CRHBP) SNP rs1500 was associated with reduced cocaine abuse after 1 year in methadone maintenance treatment (MMT) for heroin addiction, we evaluated the association of additional 28 selected SNPs, in 17 stress-related genes, with MMT outcome.
The distribution of genotypes of each SNP by cocaine abuse after 1 year in MMT was assessed under the dominant and recessive models using χ2. Cumulative retention (up to 26.5 years) was studied using Kaplan-Meier analyses. Logistic regression and Cox model were used for multivariate analyses.
Of a nonselective sample of 404 patients, 25 patients with <50% Europeans/Middle Eastern ancestry were excluded. Of the remaining 379 patients, 330 (87.1%) stayed at least 1 year in treatment. Four SNPs were associated with cocaine abuse after 1 year in MMT. A lower proportion of cocaine abusers was found in the groups of subjects with the following genotypes: arginine vasopressin (AVP) SNP rs2282018 CC, CRHBP rs7728378 TT, galanin rs3136541 TT/TC, and neuropeptide Y receptor Y1 (NPY1R) rs4518200 AA. The following independent variables were associated with lack of cocaine in urine after 1 year (multivariate analyses): CRHBP rs7728378 TT, NPY1R rs4518200 AA, no cocaine in urine on admission, as well as opiate and benzodiazepine use after 1 year in MMT. Cumulative retention (n = 379) was longer in carriers of AVP rs2282018 CC (13.7 years, 95% CI 11.1-16.2) versus TT/TC genotypes (10.5, 95% CI 9.4-11.5) (p = 0.0230) Conclusions: The study suggests that a reduction in cocaine abuse and longer retention among MMT patients is mediated in part by variants in stress-related genes and is a step toward precision medicine.
CRH 结合蛋白(CRHBP)SNP rs1500 与海洛因成瘾患者接受美沙酮维持治疗(MMT)1 年后可卡因滥用减少有关,因此我们评估了 17 个应激相关基因中另外 28 个选定 SNP 的基因型与 MMT 结果的相关性。
使用 χ2 评估 1 年后 MMT 中每个 SNP 基因型与可卡因滥用的分布,使用显性和隐性模型进行评估。使用 Kaplan-Meier 分析评估至 26.5 年的累积保留率。使用逻辑回归和 Cox 模型进行多变量分析。
在非选择性的 404 例患者中,排除了 25 例欧洲/中东血统比例<50%的患者。在剩余的 379 例患者中,330 例(87.1%)至少在治疗中停留 1 年。有 4 个 SNP 与 MMT 后 1 年的可卡因滥用有关。在具有以下基因型的受试者中,可卡因滥用者的比例较低:血管加压素(AVP)SNP rs2282018 CC、CRHBP rs7728378 TT、甘丙肽 rs3136541 TT/TC 和神经肽 Y 受体 Y1(NPY1R)rs4518200 AA。以下独立变量与 1 年后尿液中无可卡因有关(多变量分析):CRHBP rs7728378 TT、NPY1R rs4518200 AA、入院时尿液中无可卡因以及 MMT 后 1 年内阿片类药物和苯二氮䓬类药物的使用。在 379 例可随访者中,AVP rs2282018 CC(13.7 年,95%CI 11.1-16.2)携带者的累积保留时间(n = 379)长于 TT/TC 基因型(10.5,95%CI 9.4-11.5)(p = 0.0230)。结论:该研究表明,减少 MMT 患者的可卡因滥用和延长保留时间部分是由应激相关基因的变异介导的,这是迈向精准医学的一步。